Why Viking Therapeutics Stock Was So Healthy on Wednesday
Viking Therapeutics (NASDAQ: VKTX), a biotech stock that has rocketed to prominence thanks to one of its investigational drugs, gave investors more reason to like it on Wednesday. The company's share price rose by almost 2% following an analyst's bullish new research note; that increase stood in positive contrast to the 0.2% decline of the S 500 index.
The author of that note was Oppenheimer's Jay Olson, who reiterated his outperform (i.e., buy) recommendation on Viking stock, and his $138-per-share price target.
The biotech has appeared on the radars of numerous analysts and many investors because of its VK2735, an investigational drug that targets obesity. This is the hottest segment of the pharmaceutical market, with GLP-1 medications flying off pharmacy shelves in this country. VK2735 has demonstrated good efficacy in clinical testing so far, raising hopes that it could be a blockbuster in a market that still has room for competition.
Source Fool.com
Viking Therapeutics Inc Stock
With 6 Buy predictions and not the single Sell prediction the community is currently very high on Viking Therapeutics Inc.
As a result the target price of 45 € shows a very positive potential of 83.64% compared to the current price of 24.51 € for Viking Therapeutics Inc.
